NasdaqGM:ZLABBiotechs
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New AUGTYRO Approval And Pipeline Progress
Regulatory catalyst and expanding oncology reach
Zai Lab (ZLAB) has drawn fresh investor attention after China’s National Medical Products Administration approved a supplemental New Drug Application for AUGTYRO (repotrectinib) in NTRK fusion positive solid tumors, which broadens its potential treatment reach.
See our latest analysis for Zai Lab.
Despite the recent product approvals and pipeline updates, Zai Lab’s share price at US$18.58 reflects mixed momentum, with a 30 day share price...